We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Oral Bacteria May Cause Colorectal Cancer

By LabMedica International staff writers
Posted on 27 Aug 2013
Gut microbes have been linked to colorectal cancer, but it still unclear whether and how they might cause tumors to form in the first place. More...


Bacteria found in the mouth, known as Fusobacterium, stimulate poor immune responses, and turn on cancer growth genes to generate colorectal tumors; data, which could lead to more effective strategies for the early diagnosis, prevention, and treatment of colorectal cancer.

In recent studies, teams of scientists at the Dana-Farber Cancer Institute (Boston, MA, USA) found that Fusobacterium are prevalent in human adenomas, which are benign tumors that can become malignant over time, suggesting that these bacteria contribute to early stages of tumor formation. These bacteria accelerated the formation of tumors by attracting immune cells called myeloid cells, which invade tumors and stimulate inflammatory responses that can cause cancer.

In a separate study, scientists at the Case Western Reserve University (Cleveland, OH, USA) discovered that Fusobacterium nucleatum rely on a molecule called Fusobacterium adhesin A (FadA), which is found on the surface of these bacterial cells, to attach to and invade human colorectal cancer cells. FadA then turns on cancer growth genes, stimulates inflammatory responses in these cells, and promotes tumor formation. The FadA levels were much higher in tissues from patients with adenomas and colorectal cancer compared with healthy individuals. They also identified a compound that can prevent FadA's effects on cancer cells.

Wendy S. Garrett, MD, PhD, one of the senior authors, said, “Fusobacterium may provide not only a new way to group or describe colon cancers but also, more importantly, a new perspective on how to target pathways to halt tumor growth and spread." The authors concluded that unlike other bacteria linked to colorectal carcinoma, F. nucleatum does not exacerbate colitis, enteritis, or inflammation-associated intestinal carcinogenesis. However, their data suggest that, through recruitment of tumor-infiltrating immune cells, Fusobacterium generate a proinflammatory microenvironment that is conducive for colorectal neoplasia progression. The studies were published on August 14, 2013, in the journal Cell Host & Microbe.

Related Links:

Dana-Farber Cancer Institute
Case Western Reserve University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.